| Outcome Measures: |
Primary: Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods, A time adjusted mean change in hemoglobin (Hb) concentration was calculated using an area under the curve (AUC) approach, for both periods separately. Change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb value from the average evaluation period Hb value. All blood samples for Hb measurements were taken prior to study drug administration. Analysis used last observation carried forward (LOCF) for missing Hb values to correct for the impact of early dropouts. The baseline period is defined as Week -4 to Week -1. The evaluation period is defined as Week 29 to Week 36., Baseline (Week -4 to Week -1) and Evaluation period (Week 29 to Week 36) | Secondary: Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration, All mean Hb values recorded during the evaluation period were calculated and subtracted from the mean baseline Hb value for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given. The evaluation period is defined as Week 29 to Week 36., Evaluation period (Week 29 to Week 36)|Number of Participants With Red Blood Cell Transfusions, The number of participants who received RBC transfusions were reported., Up to Week 36|Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths, An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly., Up to week 52|Number of Participants With Marked Laboratory Abnormalities, A marked abnormality range was defined as above and/or below a value which was considered to be potentially clinically relevant. Marked laboratory abnormalities were analyzed according to the Roche specified limits for the reference range of the following laboratory parameters: White blood cells (WBC) (3.0- 18.0 10\^9/L), platelets (100 - 550 10\^9/L), alanine aminotransferase (ALAT) (0 - 110 units per liter \[U/L\]), alkaline phosphatase (ALP \[0 - 220 U/L\]), aspartate aminotransferase (ASAT) (0 - 80 U/L), albumin \>= 30 g/L, phosphate (0.75 - 1.60 millimoles per liter \[mmol/L\]), potassium (2.9 - 5.8 mmol/L), glucose (2.80 - 11.10 mmol/L)., Up to week 52|Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants, Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in haemodialysis participants., From Baseline (Week -4 to Week -1) to Week 36 and Week 52|Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants, Pulse rate in beats per minute (BpM) was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in haemodialysis participants., From Baseline (Week -4 to Week -1) to Week 36 and Week 52|Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants, Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in peritoneal dialysis participants., From Baseline (Week -4 to Week -1) to Week 36 and Week 52|Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants, Pulse rate in BpM was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in peritoneal dialysis participants., From Baseline (Week -4 to Week -1) to Week 36 and Week 52
|
| Locations: |
Hot Springs, Arkansas, 71901, United States|Los Angeles, California, 90033, United States|Riverside, California, 92501, United States|Sacramento, California, 95816-5119, United States|San Jose, California, 95116-1906, United States|Boston, Massachusetts, 02130, United States|Springfield, Massachusetts, 01107, United States|Detroit, Michigan, 48202-2689, United States|Brooklyn Center, Minnesota, 55430, United States|Raleigh, North Carolina, 27609, United States|Winston-salem, North Carolina, 27157-1023, United States|Toledo, Ohio, 43606, United States|Portland, Oregon, 97210, United States|Dallas, Texas, 75216, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 78229, United States|Morgantown, West Virginia, 26506, United States|Bruxelles, 1090, Belgium|Edegem, 2650, Belgium|Gent, 9000, Belgium|Hasselt, 3500, Belgium|Curitiba, 81050-090, Brazil|Sao Paulo, 03065-000, Brazil|Sao Paulo, 04039-000, Brazil|Brno, 656 91, Czech Republic|Ostrava, 708 52, Czech Republic|Plzen, 304 60, Czech Republic|Odense, 5000, Denmark|HUS, 00029, Finland|Tampere, 33521, Finland|Turku, 20521, Finland|Bayonne, 64115, France|Boulogne, 62321, France|Cabestany, 66330, France|Caen, 14033, France|Limoges, 87042, France|Nimes, 30029, France|Pantin, 93500, France|Poitiers, 86021, France|Saint-germain-en-laye, 78100, France|St Priest En Jarez, 42055, France|Thionville, 57126, France|Tours, 37044, France|Bad Hersfeld, 36251, Germany|Berlin, 12045, Germany|Kaiserslautern, 67655, Germany|Budapest, 1076, Hungary|Budapest, 1134, Hungary|Debrecen, 4032, Hungary|Miskolc, 3526, Hungary|Pecs, 7624, Hungary|Cremona, 26100, Italy|Lecco, 23900, Italy|Mestre, 30174, Italy|Modena, 41100, Italy|Prato, 50047, Italy|Venezia, 30122, Italy|Cuernavaca, 62448, Mexico|Mexico City, 14000, Mexico|Christchurch, New Zealand|Wellington, New Zealand|Panama City, 0, Panama|Gdansk, 80-211, Poland|Kielce, 25-736, Poland|Krakow, 31-501, Poland|Wroclaw, 50-417, Poland|Ponce, 00732, Puerto Rico|Durban, South Africa|Alcorcon, 28922, Spain|Barcelona, 08035, Spain|Madrid, 28006, Spain|Madrid, 28046, Spain|Palma de Mallorca, 07198, Spain|Pamplona, 31008, Spain|Santiago de Compostela, 15706, Spain|Huddinge, 14186, Sweden|Karlstad, 65185, Sweden|Taichung, 407, Taiwan|Taipei, 100, Taiwan|Bangkok, 10310, Thailand|Bangkok, 10400, Thailand|Phitsanulok, 65000, Thailand|Belfast, BT9 7LJ, United Kingdom|Cambridge, CB2 2QQ, United Kingdom|Dundee, DD1 9SY, United Kingdom|Exeter, EX2 5DW, United Kingdom|Leicester, LE5 4PW, United Kingdom|London, SE1 9RT, United Kingdom|London, SE22 8PT, United Kingdom|London, SW17 0RE, United Kingdom
|
